Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia Abstract #2867

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Aim(s): Evaluate the efficacy and toxicity of EVE in Russian patient population and identify factors of prognostic value.
Materials and methods: 90 pts (30 men, 60 women) with well-differentiated NETs (pNETs - 35 pts, gastrointestinal - 26, lungs -12, CUP - 14, uterus - 2, retroperitoneal space - 1 patient) were evaluated. Functional tumors - 48.9% (clinical manifestations - 6 pts, clinical manifestations + biochemical parameters - 38 pts). Only an increase in biochemical markers in 36.7% pts. G1 – 23,3%, G2-75,6%, G3- 1,1%. 61 pts- surgical treatment, 57 - chemotherapy, 24 –α-INF, 69 - SSA, 7 - sunitinib, 7 pts - did not receive treatment before. Factors analyzed: localization, metastasis zones, surgery, SSA, ECOG, carcinoid syndrome, chromogranin, serotonin. Univariate and multivariate analysis was carried out.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2741 Histologic Grading of Neuroendocrine Tumors and Its Relationship of Survival
Introduction: Current classification divides NENs into neuroendocrine tumors (NETs) and neuroendocrine carcinoma (NEC). NENs at different anatomic sites require site-specific applications for the classification.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: student Sofija Vilisova